Patent EA-003699-B1 (EA)
Title: Topical administration of oxazolidinones for transdermal delivery
Inventor: FORD CHARLES W
IPC: A61K31/422
Filed: 1999-05-26
Abstract: 1. Method for treating infections selected from the group consisting of ear infections, skin and soft tissue infections, acne, infected wounds, bacteremia, in a useful warm blooded mammal who is in need of such treatment which comprises topical administration of a pharmaceutical formulation containing a transdermally effective amount of the oxazolidinone, selected from group, consisting of: S)-N-[[3-[3-fluoro-4-[4-(hydroxyacetyl)-1-piperazinyl]-phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide, (S)-N-[[3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide, [4(S)-cis]-(-)-N-[[3-[3-fluoro-4-(tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide, N-((5S)-3-(3-fluoro-4-(4-(2-fluoroethyl)-3-oxopiperazin-1-yl)phenyl}-2-oxooxazolidin-5-ylmethyl)acetamide, (S)-N-[[3-[5-(3-pyridyl)thiophen-2-yl]-2-oxo-S-oxazolidinyl]methyl]acetamide and (S)-N-[[3-[5-(4-pyridyl)pyrid-2-yl)-2-oxo-5-oxazolidinyl]methyl]acetamide hydrochloride, or a pharmaceutically acceptable salts thereof. 2. Method according to claim 1, wherein the oxazolidinone is selected from a group consisting of (S)-N-[[3-[3-fluoro-4-[4-(hydroxyacetyl)-1-piperazinyl]-phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide, (S)-N-[[3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide and [4(S)-cis]-(-)-N-([3-[3-fluoro-4-(tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide. 3. Method according to claim 1, wherein the oxazolidinone is: (S)-N-[[3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide. 4. Method according to claim 1-3 where the useful warm-blooded mammal is a human. 5. Method according to claim 1-3 where the useful warm-blooded mammal is a dog or cat. 6. Pharmaceutical composition containing a transdermally effective amount of the oxazolidinone, selected from group, consisting of: S)-N-[[3-[3-fluoro-4-[4-(hydroxyacetyl)-1-piperazinyl]-phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide, (S)-N-[[3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide, [4(S)-cis]-(-)-N-[[3-[3-fluoro-4-(tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide, N-((5S)-3-(3-fluoro-4-(4-(2-fluoroethyl)-3-oxopiperazin-1-yl)phenyl}-2-oxooxazolidin-5-ylmethyl)acetamide, (S)-N-[[3-[5-(3-pyridyl)thiophen-2-yl]-2-oxo-S-oxazolidinyl]methyl]acetamide and (S)-N-[[3-[5-(4-pyridyl)pyrid-2-yl)-2-oxo-5-oxazolidinyl]methyl]acetamide hydrochloride, or a pharmaceutically acceptable salts thereof and, pharmaceutically acceptable stuffs, for treating of infections selected from a group, comprising ear infections, soft tissue and acne infections, which are not on the skin surface of useful warm blooded mammal. 7. Pharmaceutical composition according to claim 6 where the infection is an ear infection. 8. Pharmaceutical composition according to claim 7 is a solution, suspension or emulsion. 9. Pharmaceutical composition according to claim 8 wherein the transdermally effective amount of oxazolidinone is from about 0.1 to about 10%. 10. Pharmaceutical composition according to claim 9 where the transdermally effective amount of oxazolidinone is from about 0.2 to about 2%. 11. Pharmaceutical composition according to claim 6 where the infection is a skin and soft tissue infections. 12. Pharmaceutical composition according to claim 11 where the pharmaceutical formulation is a cream, ointment, gel and emulsion. 13. Pharmaceutical composition according to claim 12 where the transdermally effective amount is from about 0.2 to about 40%. 14. Pharmaceutical composition according to claim 12 where the transdermally effective amount is from about 0.4 to about 10%. 15. Pharmaceutical composition according to claim 6 where the infection is acne. 16. Pharmaceutical composition according to claim 15 is a cream, ointment, gel, emulsion, suspension, solution and patch. 17. Pharmaceutical composition according to claim 16 where the transdermally effective amount is from about 0.1 to about 10%. 18. Pharmaceutical composition according to claim 17 where the transdermally effective amount is from about 0.2 to about 6%. 19. Pharmaceutical composition according to claim 1 where the infection is caused by Staphylococci, Streptococci and Enterococci. 20. Pharmaceutical composition according to claim 1 where the infection is caused by Staphylococci. 21. Pharmaceutical composition according to claim 1 where the oxazolidinone is administered from 2 thru 4 times daily.